THE RIGHT DIAGNOSTIC CAN SAVE YOUR LIFE
We provide the most comprehensive test on the market
ARE YOU A DOCTOR OF A PATIENT?
We be happy to share our information with you
WHY WE ARE DOING IT
Only 1 out of 4 approved cancer treatments prolong life
WHAT WE DO
We are sequencing RNA to identify the best drug for the patient and the best patient for the drug
Only 1 out of 4 cancer treatments prolong life
From a genetic perspective, every cancer is unique. Yet the treatment most patients are offered is a standard treatment based on tissue of origin and stage.
Sequencing provides a paradigm shift
Sequencing has enabled a paradigm shift away from looking at colored cells in a microscope to define the cancer by its genetic drivers. The sequence data enabling the doctor to diagnose aggressive cancers early AND identify more effective treatments for later stage cancers with ONE comprehensive test.
Cancer is no longer mainly defined by tissue of origin
In many cases the same genetic alteration can be driving breast cancer in one patient, and lung cancer in another, opening up for many more treatment options.
Often the test can identify a less toxic and more effective treatment
Genetic testing using sequencing, opens up for treating with new types of drugs that target these genetic changes. Often the test can identify a less toxic and more effective targeted treatment with less side effects.
How we do it: OneRNA
OneRNA assist doctors select the best drug for their patient, and Pharma companies select the best patient for their drug
OneRNATM is a novel sample prep method that uniquely extracts RNA from the cells in a manner that makes it easy to later identify and quantify the RNAs using sequencing. Once the sample has been prepared, it is sequenced on an Illumina NextGen system. The analysis of the data is performed using a HIPAA-compliant cloud-based solution developed in collaboration with IBM. This cloud solution generates a clinically actionable report for each tumor based on its gene expression profile.
Are you a doctor or a patient?
Finding the right drug for your patient Click here to learn more
Our OneRNA report can identify actionable alterations and link them to approved drugs and drugs in clinical development. We partner with doctors to accelerate the delivery of more effective care in oncology.
Are you developing new drugs ?
Finding the right patient for your drug click here to learn more
OneRNA™ can assist you in selecting the right patients for your clinical trial. Reducing the number of different test to ONE, without compromising the number of markers you want to include. In fact you can have it all +20,000 RNA’s in ONE assay. Furthermore adding a new marker is a simple update to our cloud-based software which we can do retrospectively. As such, OneRNA™is uniquely able to keep pace with rapidly evolving clinical research and cancer drug development. Finally we can help you focus on the right indication, expand your label on existing drugs, and create responder algorithms rather than relying on one marker as a companion diagnostic.
WHO WE ARE
Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies
Chief Medical Officer
Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.
Chief Operating Officer
Tanya Kanigan, COO has a post-doctoral degree from MIT and developed the OpenArray, which was then spun out into BioTrove and sold to Life Technology.
Morten Middelfart, CIO holds two Ph.D.'s; one in data mining and machine learning, and one in business management. He has seven U.S. patents and 25 worldwide patents in his field and +20 years of analyzing Big Data.
WHO'S TALKING ABOUT US
We have been featured in GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Impact Investors such as Investor Circle, the largest impact investment angel groups in the world and a family office; Centurion Holding in New York.
We are a Springboard alum company and among the 500 women owned technology companies they have supported
Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Tech Challenge and invited to dinner with Branson on Necker’s Island, selected into the top 10 diagnostic companies at the Molecular Tri-Conference and then finalish in Top 100 Red Herring
PRESIDENT OBAMA'S MOONSHOT PROGRAM
Lead by Vice President Joe Biden - interview from Davos
US Vice-President Joe Biden convenes international leaders in cancer research, cancer treatment and data science to discuss potential opportunities to advance the pace of progress in the fight against cancer.
Speakers: Paula T. Hammond, Jennifer Doudna, Sylvia Mathews Burwell, Francis S. Collins, Joseph R. Biden Jr, Elizabeth Blackburn, Bill McDermott, Delos M. (Toby) Cosgrove, José Baselga, Charles Sawyers, David B. AgusTopics: Health, Fourth Industrial Revolution
WANT TO LEARN MORE ?
We help doctors select the best drug for their patient, and pharma companies select the best patient for their drug
The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.
Follow us on twitter
SHARING OUR OPPINIONS
Welcome to the blog - feel free to share !